Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;42(8):514-521.

Cancer Immunotherapy, Part 3: Challenges and Future Trends

C Lee Ventola

Cancer Immunotherapy, Part 3: Challenges and Future Trends

C Lee Ventola. P T. 2017 Aug.

Abstract

Despite dramatic breakthroughs, obstacles remain for the field of immunotherapy in cancer. These include the inability to predict treatment efficacy and patient response; the need for improved biomarkers; the development of resistance to immunotherapies; the lack of optimized clinical study designs; and high costs. Are solutions in sight?

PubMed Disclaimer

Figures

Figure 1
Figure 1
One-Year Per-Patient Costs for Treating Selected Cancers With Immune Checkpoint Blockers
Figure 2
Figure 2
One-Year Worldwide Costs for Treating Selected Cancers With Immune Checkpoint Blockers
See this image and copyright information in PMC

Similar articles

  • Circulating biomarkers predictive of tumor response to cancer immunotherapy.
    Lee EY, Kulkarni RP. Lee EY, et al. Expert Rev Mol Diagn. 2019 Oct;19(10):895-904. doi: 10.1080/14737159.2019.1659728. Epub 2019 Sep 10. Expert Rev Mol Diagn. 2019. PMID: 31469965 Free PMC article. Review.
  • A Blueprint to Advance Colorectal Cancer Immunotherapies.
    Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB. Le DT, et al. Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16. Cancer Immunol Res. 2017. PMID: 29038296
  • Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M. Masucci GV, et al. J Immunother Cancer. 2016 Nov 15;4:76. doi: 10.1186/s40425-016-0178-1. eCollection 2016. J Immunother Cancer. 2016. PMID: 27895917 Free PMC article. Review.
  • Canine cancer immunotherapy studies: linking mouse and human.
    Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, Culp WTN, Sparger EE, Rebhun RB, Monjazeb AM, Murphy WJ, Canter RJ. Park JS, et al. J Immunother Cancer. 2016 Dec 20;4:97. doi: 10.1186/s40425-016-0200-7. eCollection 2016. J Immunother Cancer. 2016. PMID: 28031824 Free PMC article. Review.
  • Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
    Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA. Yuan J, et al. J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. J Immunother Cancer. 2016. PMID: 26788324 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immuno therapies, their safety and toxicity. Expert Opin Drug Saf. 2013;12(5):631–645. - PubMed
    1. Chiriva-Internati M, Bot A. A new era in cancer immunotherapy: discovering novel targets and reprogramming the immune system. Int Rev Immunol. 2015;34(2):101–103. - PubMed
    1. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–3337. - PMC - PubMed
    1. Pardoli D. Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol. 2015;42(4):523–538. - PMC - PubMed
    1. Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551–1566. - PubMed

LinkOut - more resources